Phio Pharmaceuticals Changes Auditors
Ticker: PHIO · Form: 8-K · Filed: Apr 22, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Phio swapped accountants from CohnReznick to EisnerAmper, effective April 17, 2025.
AI Summary
Phio Pharmaceuticals Corp. announced on April 17, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, CohnReznick LLP, and has appointed EisnerAmper LLP as its new principal accountant. This change is effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.
Risk Assessment
Risk Level: low — This filing reports a routine change in the company's independent auditor, which is a common corporate event.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- CohnReznick LLP (company) — Former certifying accountant
- EisnerAmper LLP (company) — New certifying accountant
- April 17, 2025 (date) — Effective date of auditor change
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective as of April 17, 2025.
Who was Phio Pharmaceuticals Corp.'s former certifying accountant?
Phio Pharmaceuticals Corp.'s former certifying accountant was CohnReznick LLP.
Who has been appointed as Phio Pharmaceuticals Corp.'s new principal accountant?
EisnerAmper LLP has been appointed as Phio Pharmaceuticals Corp.'s new principal accountant.
Did Phio Pharmaceuticals Corp. have any disagreements with their former accountant?
The filing does not mention any disagreements between Phio Pharmaceuticals Corp. and CohnReznick LLP.
What is the address of Phio Pharmaceuticals Corp.'s principal executive offices?
The address of Phio Pharmaceuticals Corp.'s principal executive offices is 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2025 regarding Phio Pharmaceuticals Corp. (PHIO).